Comparative nephrotoxicity of cisplatin and nedaplatin: Mechanisms and histopathological characteristics

Journal of Toxicologic Pathology

Volumn 24, Issue 2, 2011, Pages 87-94

  Uehara, Takeki ^a   Yamate, Jyoji ^b   Torii, Mikinori ^a   Maruyama, Toshiyuki ^a  

^a SHIONOGI AND CO LTD   (Japan)

^b Osaka Prefecture University   (Japan)

Author keywords

Cisplatin; Kidney; Nedaplatin; Nephrotoxicity; Renal papilla; Toxicogenomics

Indexed keywords

CISPLATIN; GAMMA GLUTAMYLTRANSFERASE; GLUTATHIONE; HEME OXYGENASE 1; METALLOTHIONEIN I; NEDAPLATIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE DEHYDROGENASE; SUPEROXIDE DISMUTASE;

APOPTOSIS; CALCIUM HOMEOSTASIS; CELL ADHESION; CELL CYCLE REGULATION; CELL INFILTRATION; CELL MIGRATION; CONCENTRATION RESPONSE; CYTOTOXICITY; DILATATION; DISEASE COURSE; DNA METABOLISM; DOWN REGULATION; DRUG EXCRETION; DRUG MECHANISM; DRUG UPTAKE; EXPERIMENTAL ANIMAL; FIBROSIS; GENE EXPRESSION PROFILING; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; KIDNEY PAPILLA NECROSIS; KIDNEY PROXIMAL TUBULE; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; NECROSIS; NEPHROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; REVIEW; TISSUE REGENERATION; UPREGULATION;

EID: 79960447444     PISSN: 09149198     EISSN: None     Source Type: Journal    
DOI: 10.1293/tox.24.87     Document Type: Review

References (74)

1. Rozencweig M, von Hoff DD, Slavik M, and Muggia FM. Cisdiamminedichloroplatinum (II). A new anticancer drug. Ann Intern Med. 86: 803-812. 1977.[Medline]
2. Prestayko AW, D'Aoust JC, Issell BF, and Crooke ST. Cispl-atin (cis-diamminedichloroplatinum II). Cancer Treat Rev. 6: 17-39. 1979. [Medline] [CrossRef]
3. Loehrer PJ, and Einhorn LH. Drugs fve years later. Cispla-tin. Ann Intern Med. 100: 704-713. 1984. [Medline]
4. Lebwohl D, and Canetta R. Clinical development of platinum complexes in cancer therapy: an historical perspective and an update. Eur J Cancer. 34: 1522-1534. 1998. [Med-line] [CrossRef]
5. Meyer KB, and Madias NE. Cisplatin nephrotoxicity. Miner Electrolyte Metab. 20: 201-213. 1994.[Medline]
6. McKeage MJ. Comparative adverse effect profiles of platinum drugs. Drug Saf. 13: 228-244. 1995.[Medline] [Cross-Ref]
7. Santoso JT, Lucci JA, Coleman RL, Schafer I, and Hannigan EV. Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial. Cancer Chemother Pharmacol. 52: 13-18. 2003.[Medline] [Cross-Ref]
8. Goldstein RS, and Mayor GH. Minireview. The nephro-toxicity of cisplatin. Life Sci. 32: 685-690. 1983.[Medline] [CrossRef]
9. Safrstein R, Winston J, Goldstein M, Moel D, Dikman S, and Guttenplan J. Cisplatin nephrotoxicity. Am J Kidney Dis. 8: 356-367. 1986.[Medline]
10. Menczer J, Ben-Baruch G, Rizel S, and Brenner H. Acute renal failure associated with intraperitoneal cisplatin chemotherapy with systemic thiosulfate protection in ovarian cancer patients. Eur J Gynaecol Oncol. 12: 403-406. 1991. [Medline]
11. Ali BH, and Al Moundhri MS. Agents ameliorating or augmenting the nephrotoxicity of cisplatin and other platinum compounds: a review of some recent research. Food Chem Toxicol. 44: 1173-1183. 2006. [Medline] [CrossRef]
12. Boulikas T, and Vougiouka M. Cisplatin and platinum drugs at the molecular level. Oncol Rep. 10: 1663-1682. 2003. [Medline]
13. Fukuda M, Shinkai T, Eguchi K, Sasaki Y, Tamura T, Ohe Y, Kojima A, Oshita F, Hara K, and Saijo N. Phase II study of (glycolato-O,O) diammineplatinum(II), a novel platinum complex, in the treatment of non-small-cell lung cancer. Cancer Chemother Pharmacol. 26: 393-396. 1990. [Med-line] [CrossRef]
14. Taguchi T, Wakui A, Nabeya K, Kurihara M, Isono K, Kakegawa T, and Ota K. A phase II clinical study of cis-diammine glycolato platinum, 254-S, for gastrointestinal cancers. Gan To Kagaku Ryoho. 19: 483-488. 1992 (In Japanese).[Medline]
15. Inuyama Y, Miyake H, Horiuchi M, Hayasaki K, Komiya-ma S, and Ota K. A late phase II clinical study of cis-diam-mine glycolato platinum, 254-S, for head and neck cancers. Gan To Kagaku Ryoho. 19: 871-877. 1992 (In Japanese). [Medline]
16. Akaza H, Togashi M, Nishio Y, Miki T, Kotake T, Mat-sumura Y, Yoshida O, and Aso Y. Phase II study of cis-diammine(glycolato)platinum, 254-S, in patients with advanced germ-cell testicular cancer, prostatic cancer, and transitional-cell carcinoma of the urinary tract. Cancer Chemother Pharmacol. 31: 187-192. 1992. [Medline] [CrossRef]
17. Kato T, Nishimura H, Yakushiji M, Noda K, Terashima Y, Takeuchi S, Takamizawa H, Suzuki M, Arai M, and Ota M. Phase II study of 254-S (cis-diammine glycolato platinum) for gynecological cancer. Gan To Kagaku Ryoho. 19: 695-701. 1992 (In Japanese).[Medline]
18. Dobyan DC. Long-term consequences of cis-platinum-induced renal injury: a structural and functional study. Anat Rec. 212: 239-245. 1985. [Medline] [CrossRef]
19. Leibbrandt ME, Wolfgang GH, Metz AL, Ozobia AA, and Haskins JR. Critical subcellular targets of cisplatin and related platinum analogs in rat renal proximal tubule cells. Kidney Int. 48: 761-770. 1995. [Medline] [CrossRef]
20. Townsend DM, Deng M, Zhang L, Lapus MG, and Hanigan MH. Metabolism of cisplatin to a nephrotoxin in proximal tubule cells. J Am Soc Nephrol. 14: 1-10. 2003. [Medline] [CrossRef]
21. Dobyan DC, Levi J, Jacobs C, Kosek J, and Weiner MW. Mechanism of cis-platinum nephrotoxicity: II. Morpholog-ic observations. J Pharmacol Exp Ther. 213: 551-556. 1980. [Medline]
22. Dobyan DC, Hill D, Lewis T, and Bulger RE. Cyst formation in rat kidney induced by cis-platinum administration. Lab Invest. 45: 260-268. 1981. [Medline]
23. Chopra S, Kaufman JS, Jones TW, Hong WK, Gehr MK, Hamburger RJ, Flamenbaum W, and Trump BF. Cis-diam-minedichlorplatinum-induced acute renal failure in the rat. Kidney Int. 21: 54-64. 1982. [Medline] [CrossRef]
24. Uehara T, Watanabe H, Itoh F, Inoue S, Koshida H, Na-kamura M, Yamate J, and Maruyama T. Nephrotoxicity of a novel antineoplastic platinum complex, nedaplatin: a comparative study with cisplatin in rats. Arch Toxicol. 79: 451-460. 2005. [Medline] [CrossRef]
25. Nagothu KK, Bhatt R, Kaushal GP, and Portilla D. Fibrate prevents cisplatin-induced proximal tubule cell death. Kidney Int. 68: 2680-2693. 2005. [Medline] [CrossRef]
26. Uehara T, Tsuchiya N, Masuda A, Torii M, Nakamura M, Yamate J, and Maruyama T. Time course of the change and amelioration of nedaplatin-induced nephrotoxicity in rats. J Appl Toxicol. 28: 388-398. 2008. [Medline] [CrossRef]
27. Uehara T, Miyoshi T, Tsuchiya N, Masuno K, Okada M, Inoue S, Torii M, Yamate J, and Maruyama T. Comparative analysis of gene expression between renal cortex and papilla in nedaplatin-induced nephrotoxicity in rats. Hum Exp Toxicol. 26: 767-780. 2007. [Medline] [CrossRef]
28. Safrstein R, Miller P, and Guttenplan JB. Uptake and metabolism of cisplatin by rat kidney. Kidney Int. 25: 753-758. 1984. [Medline] [CrossRef]
29. Gately DP, and Howell SB. Cellular accumulation of the anticancer agent cisplatin: a review. Br J Cancer. 67: 1171-1176. 1993. [Medline] [CrossRef]
30. Pabla N, Murphy RF, Liu K, and Dong Z. The copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity. Am J Physiol Renal Physiol. 296: F505-F511. 2009. [Medline] [CrossRef]
31. Ciarimboli G, Ludwig T, Lang D, Pavenstädt H, Koepsell H, Piechota HJ, Haier J, Jaehde U, Zisowsky J, and Schlat-ter E. Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am J Pathol. 167: 1477-1484. 2005. [Medline] [CrossRef]
32. Yonezawa A, Masuda S, Nishihara K, Yano I, Katsura T, and Inui K. Association between tubular toxicity of cispla-tin and expression of organic cation transporter rOCT2 (Sl-c22a2) in the rat. Biochem Pharmacol. 70: 1823-1831. 2005. [Medline] [CrossRef]
33. Filipski KK, Mathijssen RH, Mikkelsen TS, Schinkel AH, and Sparreboom A. Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin Pharmacol Ther. 86: 396-402. 2009. [Medline] [CrossRef]
34. Yonezawa A, Masuda S, Yokoo S, Katsura T, and Inui K. Cisplatin and oxaliplatin, but not carboplatin and neda-platin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther. 319: 879-886. 2006. [Medline] [CrossRef]
35. Yokoo S, Yonezawa A, Masuda S, Fukatsu A, Katsura T, and Inui K. Differential contribution of organic cation transporters, OCT2 and MATE1, in platinum agent-induced nephrotoxicity. Biochem Pharmacol. 74: 477-487. 2007. [Medline] [CrossRef]
36. Tanaka H, Nagasaki T, Okabe H, Uchida N, Norikura R, Inazawa K, Yamauchi A, Katsuyama Y, Segawa K, Murakami T, Adachi Y, Mizojiri K, Matsubara T, Kawai K, and Akaboshi M. Studies on the disposition of a new anti-neoplastic agent, nedaplatin. Whole-body autoradiography, blood concentration and excretion of [195mPt]nedapla-tin following intravenous administration in rats. Iyakuhin Kenkyu. 26: 887-895. 1995 (In Japanese).
37. Baliga R, Ueda N, Walker PD, and Shah SV. Oxidant mechanisms in toxic acute renal failure. Drug Metab Rev. 31: 971-997. 1999. [Medline] [CrossRef]
38. Pabla N, and Dong Z. Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies. Kidney Int. 73: 994-1007. 2008. [Medline] [CrossRef]
39. Santos NA, Catão CS, Martins NM, Curti C, Bianchi ML, and Santos AC. Cisplatin-induced nephrotoxicity is associated with oxidative stress, redox state unbalance, impairment of energetic metabolism and apoptosis in rat kidney mitochondria. Arch Toxicol. 81: 495-504. 2007. [Medline] [CrossRef]
40. Huang Q, Dunn RT, Jayadev S, DiSorbo O, Pack FD, Farr SB, Stoll RE, and Blanchard KT. Assessment of cis-platin-induced nephrotoxicity by microarray technology. Toxicol Sci. 63: 196-207. 2001. [Medline] [CrossRef]
41. Aleksunes LM, Goedken MJ, Rockwell CE, Thomale J, Manautou JE, and Klaassen CD. Transcriptional regulation of renal cytoprotective genes by Nrf2 and its potential use as a therapeutic target to mitigate cisplatin-induced nephro-toxicity. J Pharmacol Exp Ther. 335: 2-12. 2010. [Medline] [CrossRef]
42. Guerrero-Beltrán CE, Calderón-Oliver M, Tapia E, Medina-Campos ON, Sánchez-González DJ, Martínez-Martínez CM, Ortiz-Vega KM, Franco M, and Pedraza-Chaverri J. Sulforaphane protects against cisplatin-induced nephrotox-icity. Toxicol Lett. 192: 278-285. 2010. [Medline] [Cross-Ref]
43. Okuda M, Masaki K, Fukatsu S, Hashimoto Y, and Inui K. Role of apoptosis in cisplatin-induced toxicity in the renal epithelial cell line LLC-PK1. Implication of the functions of apical membranes. Biochem Pharmacol. 59: 195-201. 2000. [Medline] [CrossRef]
44. Wei Q, Dong G, Franklin J, and Dong Z. The pathological role of Bax in cisplatin nephrotoxicity. Kidney Int. 72: 53-62. 2007. [Medline] [CrossRef]
45. Park MS, De Leon M, and Devarajan P. Cisplatin induces apoptosis in LLC-PK1 cells via activation of mitochondrial pathways. J Am Soc Nephrol. 13: 858-865. 2002. [Medline]
46. Megyesi J, Udvarhelyi N, Safrstein RL, and Price PM. The p53-independent activation of transcription of p21 WAF1/ CIP1/SDI1 after acute renal failure. Am J Physiol. 271: F1211-F1216. 1996. [Medline]
47. Yu F, Megyesi J, Safrstein RL, and Price PM. Identifcation of the functional domain of p21(WAF1/CIP1) that protects cells from cisplatin cytotoxicity. Am J Physiol Renal Physi-ol. 289: F514-F520. 2005. [Medline] [CrossRef]
48. Ramesh G, and Reeves WB. TNFR2-mediated apoptosis and necrosis in cisplatin-induced acute renal failure. Am J Physiol Renal Physiol. 285: F610-F618. 2003. [Medline]
49. Faubel S, Ljubanovic D, Reznikov L, Somerset H, Dinarello CA, and Edelstein CL. Caspase-1-defcient mice are protected against cisplatin-induced apoptosis and acute tubular necrosis. Kidney Int. 66: 2202-2213. 2004. [Medline] [CrossRef]
50. Lieberthal W, Triaca V, and Levine J. Mechanisms of death induced by cisplatin in proximal tubular epithelial cells: apoptosis vs. necrosis. Am J Physiol. 270: F700-F708. 1996. [Medline]
51. Battershill JM. Toxicogenomics: regulatory perspective on current position. Hum Exp Toxicol. 24: 35-40. 2005. [Med-line] [CrossRef]
52. Heinloth AN, Irwin RD, Boorman GA, Nettesheim P, Fan-nin RD, Sieber SO, Snell ML, Tucker CJ, Li L, Travlos GS, Vansant G, Blackshear PE, Tennant RW, Cunningham ML, and Paules RS. Gene expression profling of rat livers reveals indicators of potential adverse effects. Toxicol Sci. 80: 193-202. 2004. [Medline] [CrossRef]
53. Irwin RD, Boorman GA, Cunningham ML, Heinloth AN, Malarkey DE, and Paules RS. Application of toxicogenom-ics to toxicology: basic concepts in the analysis of microar-ray data. Toxicol Pathol. 32: 72-83. 2004. [Medline] [Cross-Ref]
54. Searfoss GH, Ryan TP, and Jolly RA. The role of transcrip-tome analysis in pre-clinical toxicology. Curr Mol Med. 5: 53-64. 2005. [Medline] [CrossRef]
55. Tenhunen R, Marver HS, and Schmid R. The enzymatic conversion of heme to bilirubin by microsomal heme oxy-genase. Proc Natl Acad Sci USA. 61: 748-755. 1968. [Med-line] [CrossRef]
56. Bauer M, and Bauer I. Heme oxygenase-1: redox regulation and role in the hepatic response to oxidative stress. Anti-oxid Redox Signal. 4: 749-758. 2002. [Medline] [CrossRef]
57. Takahashi T, Morita K, Akagi R, and Sassa S. Protective role of heme oxygenase-1 in renal ischemia. Antioxid. Re-dox Signal. 6: 867-877. 2004. [Medline]
58. Chubatsu LS, and Meneghini R. Metallothionein protects DNA from oxidative damage. Biochem J. 291: 193-198. 1993. [Medline]
59. Miles AT, Hawksworth GM, Beattie JH, and Rodilla V. Induction, regulation, degradation, and biological signif-cance of mammalian metallothioneins. Crit Rev Biochem Mol Biol. 35: 35-70. 2000. [Medline] [CrossRef]
60. Hagrman D, Goodisman J, Dabrowiak JC, and Souid AK. Kinetic study on the reaction of cisplatin with metallothio-nein. Drug Metab Dispos. 31: 916-923. 2003. [Medline] [CrossRef]
61. Holmgren A. Thioredoxin and glutaredoxin systems. J Biol Chem. 264: 13963-13966. 1989. [Medline]
62. Holmgren A, and Aslund F. Glutaredoxin. Meth Enzymol. 252: 283-292. 1995. [Medline] [CrossRef]
63. Hayes JD, and Strange RC. Potential contribution of the glutathione S-transferase supergene family to resistance to oxidative stress. Free Radic Res. 22: 193-207. 1995. [Med-line] [CrossRef]
64. Moll R, Franke WW, Schiller DL, Geiger B, and Krepler R. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell. 31: 11-24. 1982. [Medline] [CrossRef]
65. Moll R. Cytokeratins as markers of differentiation in the diagnosis of epithelial tumors. Subcell Biochem. 31: 205-262. 1998. [Medline]
66. Chu PG, and Weiss LM. Keratin expression in human tissues and neoplasms. Histopathology. 40: 403-439. 2002. [Medline] [CrossRef]
67. Cooper D, Schermer A, and Sun TT. Classifcation of human epithelia and their neoplasms using monoclonal anti-bodies to keratins: strategies, applications, and limitations. Lab Invest. 52: 243-256. 1985. [Medline]
68. Cornelison TL, and Reed E. Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin. Gy-necol Oncol. 50: 147-158. 1993. [Medline] [CrossRef]
69. Uehara T, Tsuchiya N, Torii M, Yamate J, and Maruyama T. Amelioration of nedaplatin-induced nephrotoxicity by continuous infusion in rats. J Toxicol Pathol. 20: 141-147. 2007. [CrossRef]
70. Yamate J, Tatsumi M, Nakatsuji S, Kuwamura M, Kotani T, and Sakuma S. Immunohistochemical observations on the kinetics of macrophages and myofbroblasts in rat renal interstitial fbrosis induced by cis-diamminedichloroplat-inum. J Comp Pathol. 112: 27-39. 1995. [Medline] [Cross-Ref]
71. Yamate J, Ishida A, Tsujino K, Tatsumi M, Nakatsuji S, Ku-wamura M, Kotani T, and Sakuma S. Immunohistochemi-cal study of rat renal interstitial fbrosis induced by repeated injection of cisplatin, with special reference to the kinet-ics of macrophages and myofbroblasts. Toxicol Pathol. 24: 199-206. 1996. [Medline] [CrossRef]
72. Yamate J, Machida Y, Ide M, Kuwamura M, Sawamoto O, and LaMarre J. Effects of lipopolysaccharide on the appearance of macrophage populations and fbrogenesis in cispla-tin-induced rat renal injury. Exp Toxicol Pathol. 56: 13-24. 2004. [Medline] [CrossRef]
73. Yamate J, Machida Y, Ide M, Kuwamura M, Kotani T, Sawamoto O, and LaMarre J. Cisplatin-induced renal interstitial fbrosis in neonatal rats, developing as solitary nephron unit lesions. Toxicol Pathol. 33: 207-217. 2005. [Medline] [CrossRef]
74. Yamamoto E, Izawa T, Juniantito V, Kuwamura M, Sugiura K, Takeuchi T, and Yamate J. Involvement of endogenous prostaglandin E2 in tubular epithelial regeneration through inhibition of apoptosis and epithelial-mesenchymal transition in cisplatin-induced rat renal lesions. Histol Histo-pathol. 25: 995-1007. 2010. [Medline]